Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Progyny (PGNY) is Poised to Beat Earnings Estimates Again
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PGNY CEO on "Well-Positioned" Sales Year & Expanding Footprint
Pete Anevski, CEO of Progyny (PGNY), discusses his company's latest earnings and how it's poised for a "well-positioned" year. He notes general healthcare headwinds for the women's health company, though he expects Progyny to find new clients and retain current customers.
Progyny Tops EPS Forecast, Eyes Growth
Progyny (PGNY -1.68%), a pioneer in fertility benefits management, released its earnings for the fourth quarter on Feb. 27. The standout points were its impressive revenue and adjusted earnings per share (EPS) results, both of which surpassed analysts' consensus predictions.
Progyny, Inc. (PGNY) Q4 2024 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q4 2024 Earnings Conference Call February 27, 2025 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Leerink Partners John Pinney - Canaccord Genuity Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Allen Lutz - Bank of America Sarah James - Cantor Constantine Davides - Citizens JMP Jenny Shen - BTIG Operator Good day, ladies and gentlemen. Welcome to the Progyny, Inc. Fourth Quarter Earnings Conference Call.
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Progyny (PGNY) Rating Upgrade to Buy
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy.
Progyny: Rating Downgrade On Uncertain Growth Outlook
I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adjacent solutions.
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.
